Cashu
Arcellx Positioned for Growth in Reviving Biotech Sector Amid Market Uncertainties
about 1 year ago
Stocks
Health Care
aclx
Arcellx
NASDAQ: ACLX
+49.60 (+77.37%)
113.71
USD
At close at Feb 23, 21:45 UTC
Overview
Loading chart...
Key Stats
Market Cap
3.56B
Dividend Yield
0.00%
P/E Ratio
-16.32
EPS
-2.99
Revenue
76.81M
Avg. Volume
818.17K
About
What does ACLX do?
Arcellx, based in Redwood City, California, focuses on innovative immunotherapies for cancer, with its lead product, CART-ddBCMA, in pivotal Phase II trials for multiple myeloma. The company also develops two clinical-stage programs targeting BCMA and CD123 in various blood cancers.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.